For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Myriad Genetics, Inc (NASDAQ: MYGN) closed at $7.40 down -3.14% from its previous closing price of $7.64. In other words, the price has decreased by -$3.14 from its previous closing price. On the day, 2.01 million shares were traded. MYGN stock price reached its highest trading level at $7.54 during the session, while it also had its lowest trading level at $7.29.
Ratios:
For a deeper understanding of Myriad Genetics, Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.65 and its Current Ratio is at 1.82. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
On March 12, 2025, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $11.50 to $12.50.
On February 12, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $29.Craig Hallum initiated its Buy rating on February 12, 2025, with a $29 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 704189952 and an Enterprise Value of 713587072. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.81 while its Price-to-Book (P/B) ratio in mrq is 0.96. Its current Enterprise Value per Revenue stands at 0.852 whereas that against EBITDA is -26.626.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.98, which has changed by -0.60215056 over the last 52 weeks, in comparison to a change of 0.017286062 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $7.35. The 50-Day Moving Average of the stock is -28.61%, while the 200-Day Moving Average is calculated to be -59.99%.
Shares Statistics:
For the past three months, MYGN has traded an average of 1.14M shares per day and 1231140 over the past ten days. A total of 91.30M shares are outstanding, with a floating share count of 88.14M. Insiders hold about 4.37% of the company’s shares, while institutions hold 100.71% stake in the company. Shares short for MYGN as of 1743379200 were 5363278 with a Short Ratio of 4.71, compared to 1740700800 on 4906767. Therefore, it implies a Short% of Shares Outstanding of 5363278 and a Short% of Float of 8.2100004.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
